ERYP - ERYTECH Pharma Fails Primary Endpoint Goal of Phase 3 of Eryaspase in Patients with Pancreatic Cancer

ERYTECH Pharma (NASDAQ: ERYP) reported top results from Phase 3 TRYbeCA-1 clinical trial that evaluates eryaspase as second line treatment in 512 patints with metastatic pancreatic cancer.  The trial did not meet its primary endpoint of overall survival.  “While the results are disappointing, we congratulate the company for a very well managed trial in this difficult disease. With a median survival of 7.5 months, ERYTECH has created a new reference standard for clinical evaluation in second line pancreatic cancer”,said Prof. Pascal Hammel, MD, PhD, gastroenterologistoncologist at Beaujon Hospital in Paris and co-principal investigator of the TRYbeCA-1 trial. “I agree with Prof Hammel, and want to add that the results in the subgroup of fluoropyrimidine-based treatments are, with a median survival of 8 months, really remarkable and merit further investigation. Especially since this was also the better subgroup in the Phase 2b trial”, said Prof. Manuel Hidalgo, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and co-principal investigator of the study. “Pancreatic cancer is a very challenging, heterogeneous disease, and the results of the TRYbeCA-1 Phase 3 trial have now also encountered this significant hurdle.” said Dr Iman El Hariry, Chief Medical Officer of ERYTECH.

“It is very disappointing that the clinical benefit eryaspase demonstrated in the Phase 2 trial was not confirmed; however, the study has addressed important questions in the management of pancreatic cancer patients. I want to thank the patients, their families and healthcare providers, our vendors, as well as our colleagues at ERYTECH, who overcame many obstacles, including the COVID-19 pandemic, to execute this important trial. Targeting the altered asparagine and glutamine metabolism of cancer cells, well established in ALL, remains an important field of development, also for the field of solid tumors. The ERYTECH team along with its clinical advisors will review the full data analyses including the secondary and exploratory endpoints and provide a more detailed update on additional subgroup analysis after these are completed”.

The post ERYTECH Pharma Fails Primary Endpoint Goal of Phase 3 of Eryaspase in Patients with Pancreatic Cancer first appeared on Financial Buzz .

For further details see: